Boston Family Office LLC Has $7.95 Million Stock Position in Danaher Corporation $DHR

Boston Family Office LLC lifted its stake in Danaher Corporation (NYSE:DHR) by 7.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,260 shares of the conglomerate’s stock after buying an additional 2,794 shares during the period. Boston Family Office LLC’s holdings in Danaher were worth $7,953,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of DHR. OMERS ADMINISTRATION Corp grew its position in Danaher by 64.2% in the second quarter. OMERS ADMINISTRATION Corp now owns 86,775 shares of the conglomerate’s stock valued at $17,142,000 after acquiring an additional 33,916 shares during the period. M.D. Sass LLC boosted its stake in shares of Danaher by 13.8% in the 2nd quarter. M.D. Sass LLC now owns 356,654 shares of the conglomerate’s stock valued at $70,454,000 after purchasing an additional 43,333 shares in the last quarter. Capital Counsel LLC NY boosted its stake in shares of Danaher by 0.8% in the 2nd quarter. Capital Counsel LLC NY now owns 45,732 shares of the conglomerate’s stock valued at $9,034,000 after purchasing an additional 347 shares in the last quarter. Claret Asset Management Corp acquired a new stake in shares of Danaher during the 2nd quarter worth about $231,000. Finally, Edgestream Partners L.P. increased its position in shares of Danaher by 698.0% during the 2nd quarter. Edgestream Partners L.P. now owns 24,960 shares of the conglomerate’s stock worth $4,931,000 after purchasing an additional 21,832 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

DHR has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Bank of America decreased their price target on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research report on Monday, September 22nd. Robert W. Baird set a $247.00 price target on Danaher in a report on Wednesday, October 22nd. Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. increased their target price on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $243.39.

Danaher Stock Performance

Danaher stock opened at $226.24 on Monday. The company has a market cap of $159.81 billion, a PE ratio of 46.65, a PEG ratio of 3.28 and a beta of 0.81. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23. The company’s 50-day moving average is $212.20 and its two-hundred day moving average is $203.31.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same quarter in the previous year, the company earned $1.71 EPS. Danaher’s revenue was up 4.4% on a year-over-year basis. Equities analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were paid a $0.32 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the transaction, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. The trade was a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 30,248 shares of company stock worth $6,609,663 in the last three months. Insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.